Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs-Reference-Cited by-同舟云学术

Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs

Published:2021-09-17 Issue:10 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Schooley Robert T.¹,Carlin Aaron F.¹,Beadle James R.¹,Valiaeva Nadejda¹,Zhang Xing-Quan¹,Clark Alex E.¹,McMillan Rachel E.¹,Leibel Sandra L.²³,McVicar Rachael N.³⁴,Xie Jialei¹,Garretson Aaron F.¹,Smith Victoria I.¹,Murphy Joyce¹,Hostetler Karl Y.¹^ORCID

Affiliation:

1. Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, School of Medicine, La Jolla, California, USA

2. Department of Pediatrics, University of California San Diego, School of Medicine, La Jolla, California, USA

3. Sanford Consortium for Regenerative Medicine, La Jolla, California, USA

4. Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA

Abstract

Remdesivir (RDV; GS-5734) is currently the only FDA-approved antiviral drug for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The drug is approved for use in adults or children 12 years or older who are hospitalized for the treatment of COVID-19 on the basis of an acceleration of clinical recovery for inpatients with this disease.

Funder

California Institute for Regenerative Medicine

Burroughs Wellcome Fund

HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases

HHS | NIH | National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01155-21

Reference44 articles.